Mereo BioPharma (MREO) Other Accumulated Expenses (2022 - 2026)

Mereo BioPharma (MREO) has reported Other Accumulated Expenses for 5 consecutive years, with $905000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 1.23% year-over-year to $905000.0; the TTM figure through Mar 2026 stood at $905000.0 (up 1.23% YoY), while the FY2025 annual figure was $741000.0, down 32.33% from the prior year.
• Other Accumulated Expenses advanced to $905000.0 in Q1 2026 per MREO's latest filing, from $741000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $3.4 million in Q2 2024 and bottomed at $622000.0 in Q3 2025.
• Historically, Other Accumulated Expenses has averaged $1.3 million across 5 years, with a median of $905000.0 in 2026.
• On a YoY basis, Other Accumulated Expenses climbed as much as 24.51% in 2025 and fell as far as 77.38% in 2025.
• Mereo BioPharma's Other Accumulated Expenses stood at $1.1 million in 2022, then decreased by 4.67% to $1.0 million in 2023, then gained by 7.25% to $1.1 million in 2024, then plunged by 32.33% to $741000.0 in 2025, then climbed by 22.13% to $905000.0 in 2026.
• Business Quant data shows MREO's Other Accumulated Expenses at $905000.0 in Q1 2026, $741000.0 in Q4 2025, and $622000.0 in Q3 2025.